SG11201500938XA - Diagnostic assays and kits for detection of folate receptor 1 - Google Patents
Diagnostic assays and kits for detection of folate receptor 1Info
- Publication number
- SG11201500938XA SG11201500938XA SG11201500938XA SG11201500938XA SG11201500938XA SG 11201500938X A SG11201500938X A SG 11201500938XA SG 11201500938X A SG11201500938X A SG 11201500938XA SG 11201500938X A SG11201500938X A SG 11201500938XA SG 11201500938X A SG11201500938X A SG 11201500938XA
- Authority
- SG
- Singapore
- Prior art keywords
- kits
- detection
- diagnostic assays
- folate receptor
- folate
- Prior art date
Links
- 102000010451 Folate receptor alpha Human genes 0.000 title 1
- 108050001931 Folate receptor alpha Proteins 0.000 title 1
- 238000003556 assay Methods 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261695791P | 2012-08-31 | 2012-08-31 | |
US201361756254P | 2013-01-24 | 2013-01-24 | |
PCT/US2013/057682 WO2014036495A2 (en) | 2012-08-31 | 2013-08-30 | Diagnostic assays and kits for detection of folate receptor 1 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201500938XA true SG11201500938XA (en) | 2015-04-29 |
Family
ID=50184673
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201804260QA SG10201804260QA (en) | 2012-08-31 | 2013-08-30 | Diagnostic assays and kits for detection of folate receptor 1 |
SG11201500938XA SG11201500938XA (en) | 2012-08-31 | 2013-08-30 | Diagnostic assays and kits for detection of folate receptor 1 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201804260QA SG10201804260QA (en) | 2012-08-31 | 2013-08-30 | Diagnostic assays and kits for detection of folate receptor 1 |
Country Status (27)
Country | Link |
---|---|
US (6) | US9200073B2 (de) |
EP (2) | EP3712175A1 (de) |
JP (6) | JP6293147B2 (de) |
KR (4) | KR20150046316A (de) |
CN (2) | CN104755498B (de) |
AU (4) | AU2013308497B2 (de) |
BR (1) | BR112015004229B1 (de) |
CA (2) | CA2883222C (de) |
CY (1) | CY1122907T1 (de) |
DK (1) | DK2890717T3 (de) |
ES (1) | ES2788151T3 (de) |
HK (1) | HK1210188A1 (de) |
HR (1) | HRP20200482T1 (de) |
HU (1) | HUE049693T2 (de) |
IL (4) | IL299620A (de) |
LT (1) | LT2890717T (de) |
ME (1) | ME03799B (de) |
MX (1) | MX362514B (de) |
NZ (2) | NZ726258A (de) |
PL (1) | PL2890717T3 (de) |
PT (1) | PT2890717T (de) |
RS (1) | RS60217B1 (de) |
RU (1) | RU2668824C2 (de) |
SG (2) | SG10201804260QA (de) |
SI (1) | SI2890717T1 (de) |
WO (1) | WO2014036495A2 (de) |
ZA (1) | ZA201707245B (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170085143A (ko) | 2010-02-24 | 2017-07-21 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
UA113403C2 (xx) * | 2011-04-01 | 2017-01-25 | Спосіб підвищення ефективності folr1 терапії раку | |
RS60217B1 (sr) | 2012-08-31 | 2020-06-30 | Immunogen Inc | Dijagnostički testovi i kompleti za detekciju folatnog receptora 1 |
MX2015017950A (es) * | 2013-06-20 | 2016-05-10 | Morphotek Inc | Metodos para el tratamiento de cancer de ovario. |
HUE055856T2 (hu) | 2013-08-30 | 2021-12-28 | Immunogen Inc | Antitestek és vizsgálatok a folsavreceptor 1 kimutatására |
RS59644B1 (sr) * | 2013-10-08 | 2020-01-31 | Immunogen Inc | Režimi doziranja imunokonjugata anti-folr1 |
WO2015149018A1 (en) * | 2014-03-28 | 2015-10-01 | Immunogen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
TW201625301A (zh) * | 2014-06-06 | 2016-07-16 | Kyowa Hakko Kirin Co Ltd | 藉由folr1標靶藥及葉酸代謝拮抗劑用於癌症患者之治療方法與醫藥 |
EP3221356B1 (de) * | 2014-11-20 | 2020-09-02 | F.Hoffmann-La Roche Ag | T-zellen-aktivierende bispezifische antigenbindungsmoleküle gegen folr1 und cd3 |
IL257531B2 (en) | 2015-09-17 | 2023-04-01 | Immunogen Inc | Medicinal compositions containing anti-folr1 immunoconjugates |
CN105548059B (zh) * | 2016-01-29 | 2018-08-24 | 福建医科大学 | 叶酸-牛血清白蛋白-铂铋纳米复合材料 |
WO2017192863A1 (en) * | 2016-05-04 | 2017-11-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
WO2018098277A1 (en) * | 2016-11-23 | 2018-05-31 | Eisai R&D Management Co., Ltd | Anti-folate receptor alpha antibodies and uses thereof |
CN108982430B (zh) * | 2017-05-31 | 2020-09-29 | 北京大学 | 标记细菌菌群样品的试剂盒、方法及应用 |
JP2020532751A (ja) * | 2017-09-05 | 2020-11-12 | イミュノジェン, インコーポレイテッド | 患者の試料中のヒト葉酸受容体1を検出するための方法 |
CA3091683A1 (en) | 2018-03-13 | 2019-09-19 | Phanes Therapeutics, Inc. | Anti-folate receptor 1 antibodies and uses thereof |
US20220162301A1 (en) * | 2019-04-12 | 2022-05-26 | PhanesTherapeutics, Inc. | Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof |
AU2020265568A1 (en) | 2019-04-29 | 2021-11-04 | Immunogen, Inc. | Biparatopic FR-alpha antibodies and immunoconjugates |
CN112794911B (zh) * | 2021-04-14 | 2021-08-03 | 上海偌妥生物科技有限公司 | 人源化抗叶酸受体1抗体及其应用 |
CN114163520B (zh) * | 2021-11-23 | 2024-01-30 | 南京京达生物技术有限公司 | 一种血源性人IgM抗体纯化介质制备方法 |
CN117700557B (zh) * | 2024-02-05 | 2024-04-30 | 卡秋(江苏)生物科技有限公司 | 一种特异性结合叶酸受体α的抗体或抗原结合片段 |
CN117700556B (zh) * | 2024-02-05 | 2024-04-12 | 苏州百道医疗科技有限公司 | 一种抗FRα小鼠单克隆抗体及其应用 |
Family Cites Families (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2046920B1 (de) | 1969-06-19 | 1974-05-03 | Citizen Watch Co Ltd | |
US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
DE3590766T (de) | 1985-03-30 | 1987-04-23 | ||
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
GB8826530D0 (en) | 1988-11-12 | 1988-12-14 | Ped Capacitors Ltd | Electrical capacitors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US20040049014A1 (en) | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
EP0478627A4 (en) | 1989-05-16 | 1992-08-19 | William D. Huse | Co-expression of heteromeric receptors |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
EP0463151B1 (de) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Erzeugung xenogener antikörper |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6916605B1 (en) | 1990-07-10 | 2005-07-12 | Medical Research Council | Methods for producing members of specific binding pairs |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
CA2089362C (en) | 1990-08-24 | 2000-11-21 | William D. Huse | Methods of synthesizing oligonucleotides with random codons |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
ATE177782T1 (de) | 1990-12-20 | 1999-04-15 | Ixsys Inc | Optimierung von bindenden proteinen |
EP0605522B1 (de) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methoden zur Herstellung humanisierter Antikörper |
ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
DK0627940T3 (da) | 1992-03-05 | 2003-09-01 | Univ Texas | Anvendelse af immunokonjugater til diagnose og/eller terapi af vaskulariserede tumorer |
US20030148406A1 (en) | 1992-03-17 | 2003-08-07 | David John King | Multivalent antigen-binding proteins |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
WO1994018219A1 (en) | 1993-02-02 | 1994-08-18 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
EP0714409A1 (de) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antikoerper |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6828422B1 (en) | 1995-08-18 | 2004-12-07 | Morphosys Ag | Protein/(poly)peptide libraries |
DK0859841T3 (da) | 1995-08-18 | 2002-09-09 | Morphosys Ag | Protein/(poly)peptidbiblioteker |
JP2002514895A (ja) | 1995-09-28 | 2002-05-21 | アレクション、ファーマスーティカルズ、インコーポレーテッド | ブタ細胞相互作用タンパク質 |
US6331431B1 (en) | 1995-11-28 | 2001-12-18 | Ixsys, Inc. | Vacuum device and method for isolating periplasmic fraction from cells |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
EP1500329B1 (de) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Menschliche Antikörper, die ausdrücklich menschliches TNF Alpha binden |
US6596850B1 (en) | 1998-01-30 | 2003-07-22 | Ixsys, Incorporated | Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same |
AU8691398A (en) | 1997-08-04 | 1999-02-22 | Ixsys, Incorporated | Methods for identifying ligand specific binding molecules |
EP1150688A4 (de) | 1998-10-19 | 2004-06-16 | Yeda Res & Dev | Behandlung von systemischer lupus erythematodes durch herunterregulierung der autoimmunantwort auf autoantigene |
US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
JP4794789B2 (ja) | 1999-07-02 | 2011-10-19 | モルフォシス・アクチェンゲゼルシャフト | ゲノムdna断片またはestによってコードされる(ポリ)ペプチドに対する特異的結合パートナーの作成 |
IT1307309B1 (it) | 1999-12-30 | 2001-10-30 | Enea Ente Nuove Tec | Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono. |
MXPA02009454A (es) | 2000-03-31 | 2003-04-10 | Purdue Research Foundation | Metodo de tratamiento usando conjugados ligando-inmunogeno. |
DE10037759A1 (de) | 2000-08-03 | 2002-07-04 | Gruenenthal Gmbh | Screeningverfahren |
HUP0303199A2 (hu) | 2001-02-19 | 2003-12-29 | Merck Patent Gmbh | Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállítására |
US20030087250A1 (en) | 2001-03-14 | 2003-05-08 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
NZ529808A (en) | 2001-05-02 | 2007-02-23 | Purdue Research Foundation | Treatment and diagnosis of macrophage mediated disease |
US7314974B2 (en) | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
WO2003074704A1 (fr) | 2002-03-01 | 2003-09-12 | Japan Envirochemicals, Ltd. | Proteines capables de se lier aux hormones sexuelles feminines et procede de preparation |
CA2482607C (en) | 2002-04-22 | 2013-06-11 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
WO2004043989A2 (en) | 2002-11-07 | 2004-05-27 | Medarex, Inc. | Human monoclonal antibodies to heparanase |
CN102875680B (zh) | 2002-11-07 | 2015-04-22 | 伊谬诺金公司 | 抗-cd33抗体和使用其治疗急性髓性白血病的方法 |
EP1481993A1 (de) | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation der Funktion des Poliovirus-Rezeptors |
US20050255114A1 (en) | 2003-04-07 | 2005-11-17 | Nuvelo, Inc. | Methods and diagnosis for the treatment of preeclampsia |
US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
NZ568403A (en) | 2003-05-09 | 2009-10-30 | Univ Duke | CD20-specific antibodies and methods of employing same |
CA2930485C (en) | 2003-05-14 | 2018-04-10 | Immunogen, Inc. | Maytansinoid-antibody conjugate compositions |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
JP2008500949A (ja) | 2003-07-02 | 2008-01-17 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
WO2005054469A1 (en) | 2003-12-05 | 2005-06-16 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Anti-sars monoclonal antibodies |
WO2005080431A2 (en) * | 2004-02-12 | 2005-09-01 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
WO2005103716A2 (en) | 2004-04-27 | 2005-11-03 | Galapagos N.V. | Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts |
EP1685161A1 (de) | 2004-08-30 | 2006-08-02 | Lonza Biologics plc | Affinity- plus ionenaustauschchromatographie zur aufreinigung von antikörpern |
US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
WO2006055178A2 (en) | 2004-10-25 | 2006-05-26 | Merck & Co., Inc. | Anti-addl antibodies and uses thereof |
AU2005337132B2 (en) | 2004-12-21 | 2011-01-20 | Monsanto Technology, Llc | Transgenic plants with enhanced agronomic traits |
KR20070107687A (ko) | 2004-12-31 | 2007-11-07 | 제넨테크, 인크. | Br3과 결합하는 폴리펩티드, 및 그의 용도 |
CA2594297A1 (en) | 2005-01-27 | 2006-07-27 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
US7608413B1 (en) | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
EP1864133B1 (de) | 2005-03-30 | 2010-03-10 | Purdue Research Foundation | Verfahren zur prognose von brustkrebs mittels quantifizierung von zellulären folat vitamin rezeptoren |
EP2172487A1 (de) * | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antikörper mit Immuneffektoraktivität, die in Folatrezeptor alpha-positive Zellen internalisiert werden |
JP2008539693A (ja) | 2005-05-12 | 2008-11-20 | オンコセラピー・サイエンス株式会社 | 抗dsc2抗体のエフェクター機能を用いて細胞を障害する方法 |
KR101273829B1 (ko) | 2005-05-20 | 2013-06-11 | 론자 바이올로직스 피엘씨 | 포유류 숙주 세포에서의 재조합 항체의 고-수준 발현 |
CN101273063A (zh) | 2005-05-24 | 2008-09-24 | 阿维斯塔金格兰技术有限公司 | 用于b细胞淋巴瘤治疗的针对cd20的单克隆抗体的生产方法 |
US20070009434A1 (en) | 2005-07-05 | 2007-01-11 | Low Philip S | Imaging and therapeutic method using monocytes |
US7521195B1 (en) | 2005-07-21 | 2009-04-21 | Celera Corporation | Lung disease targets and uses thereof |
WO2007022416A2 (en) | 2005-08-18 | 2007-02-22 | Ramot At Tel Aviv University Ltd. | Single chain antibodies against beta-amyloid peptide |
CA2621363C (en) | 2005-09-13 | 2015-07-07 | National Research Council Of Canada | Methods and compositions for modulating tumor cell activity |
EP1938104A2 (de) | 2005-10-17 | 2008-07-02 | Institute for Systems Biology | Von gewebe und serum abgeleitete glycoproteine, und methoden zu deren verwendung |
EP1790664A1 (de) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs |
SG170749A1 (en) | 2005-12-20 | 2011-05-30 | Sbi Biotech Co Ltd | Anti-ilt7 antibody |
US8486412B2 (en) | 2006-06-01 | 2013-07-16 | Mayo Foundation For Medical Education And Research | Immunity to folate receptors |
AU2007262635B2 (en) | 2006-06-23 | 2014-09-11 | Adc Therapeutics Sa | Polynucleotides and polypeptide sequences involved in cancer |
US7910702B2 (en) | 2006-07-28 | 2011-03-22 | The Governors Of The University Of Alberta | Recombinant antibodies to sclerotinia antigens |
AU2007284651B2 (en) | 2006-08-09 | 2014-03-20 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
US20090182955A1 (en) | 2006-09-08 | 2009-07-16 | Rao Cherukuri | Application configuration across client devices of a local system |
EP1900752A1 (de) * | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Humane anti-Folatrezeptor-alpha Antikörper und -fragmente für die Radioimmuntherapie von Eierstockkrebs |
AU2007312367B2 (en) | 2006-10-12 | 2012-09-06 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis and treatment of cancer using anti-EREG antibody |
JP5632582B2 (ja) | 2006-12-14 | 2014-11-26 | 中外製薬株式会社 | 抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断 |
WO2008079466A1 (en) | 2006-12-20 | 2008-07-03 | Mmr Information Systems, Inc. | Antibodies and methods for making and using them |
US20080227704A1 (en) | 2006-12-21 | 2008-09-18 | Kamens Joanne S | CXCL13 binding proteins |
US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
EP2604284A1 (de) | 2007-02-16 | 2013-06-19 | KTB Tumorforschungsgesellschaft mbH | Rezeptor- und antigengerichtete Prodrug |
WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
WO2008145136A1 (en) | 2007-05-30 | 2008-12-04 | Aarhus Universitet | Stat3 inactivation by inhibition of the folate receptor pathway |
JP5690589B2 (ja) | 2007-06-25 | 2015-03-25 | エンドサイト・インコーポレイテッドEndocyte, Inc. | 親水性スペーサーリンカーを含有する結合体 |
CN101139613B (zh) | 2007-08-01 | 2011-06-08 | 姜荣锡 | 抗肿瘤二元多肽及其应用与制备方法 |
CN101903526B (zh) | 2007-12-21 | 2014-02-12 | 诺华股份有限公司 | 有机化合物 |
AU2009203464A1 (en) | 2008-01-11 | 2009-07-16 | Forerunner Pharma Research Co., Ltd. | Anti-CLDN6 antibody |
US8093364B2 (en) | 2008-01-18 | 2012-01-10 | Bio-Rad Laboratories, Inc. | Enhanced purification of antibodies and antibody fragments by apatite chromatography |
JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
MX2010011621A (es) | 2008-04-21 | 2011-01-14 | Swapsol Corp | Conversion de sulfuro de hidrogeno a hidrogeno. |
WO2009132081A2 (en) | 2008-04-24 | 2009-10-29 | The Research Foundation Of State University Of New York | Monoclonal antibody-based targeting of folate receptors |
UA108598C2 (xx) | 2008-04-30 | 2015-05-25 | Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери) | |
BRPI0910746B8 (pt) | 2008-04-30 | 2021-05-25 | Immunogen Inc | agente de reticulação, conjugado de agente de ligação celular-fármaco, seu uso, composto e composição farmacêutica |
US8383351B2 (en) | 2008-06-11 | 2013-02-26 | Oxford Brookes University | Antibody to inhibin/ activin β-B subunit |
US20100069298A1 (en) * | 2008-09-16 | 2010-03-18 | Robert Penny | Methods for Detecting Overexpression of SPARC and Therapeutic and Diagnostic Methods Relating to Same |
US8546425B2 (en) | 2008-09-17 | 2013-10-01 | Purdue Research Foundation | Folate receptor binding conjugates of antifolates |
WO2010033913A1 (en) | 2008-09-22 | 2010-03-25 | Icb International, Inc. | Antibodies, analogs and uses thereof |
CN101440130B (zh) | 2008-11-21 | 2011-07-27 | 中国人民解放军第四军医大学 | 一种抗人IL-13Rα2单克隆抗体的重链和轻链的可变区 |
WO2010111388A2 (en) | 2009-03-24 | 2010-09-30 | Biocept, Inc. | Devices and methods of cell capture and analysis |
CN102574915B (zh) * | 2009-08-06 | 2014-10-22 | 伊缪纳斯制药株式会社 | 特异性结合Aβ寡聚体的抗体及其用途 |
WO2011100398A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc. | Cd20 antibodies and uses thereof |
KR20170085143A (ko) * | 2010-02-24 | 2017-07-21 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
BR112013009275A2 (pt) * | 2010-10-20 | 2017-06-20 | Morphotek Inc | glicoformas de anticorpo alfa de receptor anti-folato |
ES2780192T3 (es) * | 2010-11-05 | 2020-08-24 | Eisai Inc | Folato receptor alfa como marcador diagnóstico y de pronóstico para cánceres que expresan folato receptor alfa |
MX369659B (es) | 2011-03-29 | 2019-11-15 | Immunogen Inc | Preparacion de conjugados de maitansinoides y anticuerpos mediante un proceso de una etapa. |
AU2012236403B2 (en) | 2011-03-29 | 2016-08-04 | Immunogen, Inc. | Process for manufacturing conjugates of improved homogeneity |
UA113403C2 (xx) | 2011-04-01 | 2017-01-25 | Спосіб підвищення ефективності folr1 терапії раку | |
WO2012138749A1 (en) | 2011-04-04 | 2012-10-11 | Immunogen, Inc. | Methods for decreasing ocular toxicity of antibody drug conjugates |
PL2731972T3 (pl) * | 2011-07-15 | 2018-06-29 | Eisai R&D Management Co., Ltd. | Przeciwciała skierowane przeciwko receptorowi folianowemu alfa i ich zastosowania |
RS60217B1 (sr) | 2012-08-31 | 2020-06-30 | Immunogen Inc | Dijagnostički testovi i kompleti za detekciju folatnog receptora 1 |
JP6224619B2 (ja) | 2012-12-07 | 2017-11-01 | 協和発酵キリン株式会社 | 抗folr1抗体 |
JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
EP2997044A4 (de) | 2013-05-14 | 2017-03-22 | ImmunoGen, Inc. | Dosierplan für anti-folr1-immunokonjugate |
HUE055856T2 (hu) | 2013-08-30 | 2021-12-28 | Immunogen Inc | Antitestek és vizsgálatok a folsavreceptor 1 kimutatására |
TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
RS59644B1 (sr) | 2013-10-08 | 2020-01-31 | Immunogen Inc | Režimi doziranja imunokonjugata anti-folr1 |
WO2015149018A1 (en) | 2014-03-28 | 2015-10-01 | Immunogen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
IL257531B2 (en) | 2015-09-17 | 2023-04-01 | Immunogen Inc | Medicinal compositions containing anti-folr1 immunoconjugates |
US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2013
- 2013-08-30 RS RS20200501A patent/RS60217B1/sr unknown
- 2013-08-30 BR BR112015004229-5A patent/BR112015004229B1/pt active IP Right Grant
- 2013-08-30 NZ NZ726258A patent/NZ726258A/en unknown
- 2013-08-30 CA CA2883222A patent/CA2883222C/en active Active
- 2013-08-30 MX MX2015002605A patent/MX362514B/es active IP Right Grant
- 2013-08-30 NZ NZ630433A patent/NZ630433A/en unknown
- 2013-08-30 EP EP20160627.4A patent/EP3712175A1/de active Pending
- 2013-08-30 CA CA3137438A patent/CA3137438A1/en active Pending
- 2013-08-30 KR KR1020157007933A patent/KR20150046316A/ko not_active Application Discontinuation
- 2013-08-30 SI SI201331702T patent/SI2890717T1/sl unknown
- 2013-08-30 US US14/015,653 patent/US9200073B2/en active Active
- 2013-08-30 KR KR1020207018333A patent/KR20200079565A/ko not_active Application Discontinuation
- 2013-08-30 IL IL299620A patent/IL299620A/en unknown
- 2013-08-30 PL PL13833526T patent/PL2890717T3/pl unknown
- 2013-08-30 JP JP2015530124A patent/JP6293147B2/ja active Active
- 2013-08-30 PT PT138335260T patent/PT2890717T/pt unknown
- 2013-08-30 SG SG10201804260QA patent/SG10201804260QA/en unknown
- 2013-08-30 WO PCT/US2013/057682 patent/WO2014036495A2/en active Application Filing
- 2013-08-30 HU HUE13833526A patent/HUE049693T2/hu unknown
- 2013-08-30 ES ES13833526T patent/ES2788151T3/es active Active
- 2013-08-30 DK DK13833526.0T patent/DK2890717T3/da active
- 2013-08-30 LT LTEP13833526.0T patent/LT2890717T/lt unknown
- 2013-08-30 RU RU2015104579A patent/RU2668824C2/ru active
- 2013-08-30 CN CN201380045151.2A patent/CN104755498B/zh active Active
- 2013-08-30 EP EP13833526.0A patent/EP2890717B1/de active Active
- 2013-08-30 SG SG11201500938XA patent/SG11201500938XA/en unknown
- 2013-08-30 AU AU2013308497A patent/AU2013308497B2/en active Active
- 2013-08-30 ME MEP-2020-142A patent/ME03799B/de unknown
- 2013-08-30 KR KR1020237043959A patent/KR20240005129A/ko active Search and Examination
- 2013-08-30 CN CN201910418596.XA patent/CN110294805B/zh active Active
- 2013-08-30 KR KR1020217038453A patent/KR102617499B1/ko active IP Right Grant
-
2015
- 2015-02-04 IL IL237087A patent/IL237087B/en active IP Right Grant
- 2015-10-23 US US14/921,596 patent/US9702881B2/en active Active
- 2015-11-03 HK HK15110850.1A patent/HK1210188A1/xx unknown
-
2017
- 2017-06-12 US US15/620,117 patent/US10180432B2/en active Active
- 2017-10-25 ZA ZA2017/07245A patent/ZA201707245B/en unknown
- 2017-12-25 JP JP2017247587A patent/JP6480558B2/ja active Active
-
2018
- 2018-03-20 JP JP2018052302A patent/JP2018088942A/ja not_active Withdrawn
- 2018-06-04 AU AU2018203934A patent/AU2018203934B2/en active Active
- 2018-11-28 US US16/203,276 patent/US10613093B2/en active Active
-
2019
- 2019-02-11 IL IL264770A patent/IL264770B/en active IP Right Grant
- 2019-11-11 JP JP2019203933A patent/JP2020018325A/ja active Pending
-
2020
- 2020-02-28 US US16/804,664 patent/US20200333347A1/en not_active Abandoned
- 2020-03-24 HR HRP20200482TT patent/HRP20200482T1/hr unknown
- 2020-04-30 CY CY20201100401T patent/CY1122907T1/el unknown
- 2020-07-09 AU AU2020204602A patent/AU2020204602B2/en active Active
-
2021
- 2021-02-03 IL IL280634A patent/IL280634B2/en unknown
- 2021-12-10 JP JP2021200640A patent/JP7289346B2/ja active Active
-
2022
- 2022-06-02 US US17/831,254 patent/US20230213524A1/en active Pending
-
2023
- 2023-05-30 JP JP2023088416A patent/JP2023111942A/ja active Pending
- 2023-08-04 AU AU2023210668A patent/AU2023210668A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL280634A (en) | Tests and diagnostic kits for the detection of folate receptor 1 | |
ZA201907806B (en) | Antibodies and assays for detection of folate receptor 1 | |
HK1204648A1 (en) | Methods and devices for detection and measurement of analytes | |
EP2807479A4 (de) | Vorrichtungen und verfahren zum schnellen und genauen nachweis von analyten | |
FR2989810B1 (fr) | Piece de revetement de sol pour la detection de chutes | |
GB201412804D0 (en) | Automatic synthesis of unit tests for security testing | |
EP3014505A4 (de) | Signalweganalyse zur identifizierung von diagnostischen tests | |
EP2873976A4 (de) | Detektionssystem für eine testsubstanz | |
HK1206960A1 (en) | Apparatuses for detecting and or diagnosing swallowing disorders | |
IL230693A0 (en) | Use of the i-3859 antibody for the detection and diagnosis of cancer | |
EP2917331A4 (de) | Verfahren und systeme zur verbesserten erkennung der empfindlichkeit von tests | |
IL236436A0 (en) | Kits and methods for the detection of cyanide | |
HK1204061A1 (en) | Methods and kits for detecting and diagnosing neurotrauma | |
HK1205197A1 (en) | Assays for detection of glycosaminoglycans | |
LT2800973T (lt) | Būdai ir junginiai, skirti botulino tyrimų jautrumo padidinimui | |
EP2812694A4 (de) | Tests und verfahren zur diagnose von eierstockkrebs | |
GB201203266D0 (en) | Assay for the detection of the phenylpiperazine family | |
GB201216883D0 (en) | Ultrasonic non-destructive testing of solid objects |